Skip to search formSkip to main contentSkip to account menu

SGB 1534

Known as: SGB-1534 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1993
Highly Cited
1993
A series of 2-[(substituted phenylpiperazin-1-yl)methyl]- and 2-[(substituted phenylpiperidin-1-yl)methyl]-2,3-dihydroimidazo[1,2… 
1989
1989
The comparative effects of antihypertensive agents, quinazoline or quinazolinedione residues (prazosin, bunazosin, terazosin, SGB… 
1988
1988
In order to assess the antihypertensive activities of SGB-1534, 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2, 4-(1H, 3H… 
1988
1988
Experiments in vitro and in vivo were undertaken to examine possible involvement of a central effect in the hypotensive mechanism… 
1988
1988
Serotonin has an important role in the control of blood pressure, because serotonin2 (5HT2) antagonists ameliorate hypertension… 
1987
1987
The cardiovascular effects of a novel antihypertensive agent, SGB-1534, and its alpha 1-adrenoceptor antagonism in the renal… 
1986
1986
The present study was designed to examine the antiplatelet activity of SGB-1534, 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2… 
1985
1985
The antihypertensive activities of SGB-1534, 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2,4 (1H,3H)-quinazolinedione… 
1985
1985
The present in vivo and in vitro experiment was designed to examine the hypotensive mechanisms of 3-[2-[4-(o-methoxyphenyl)-1…